• 1
    Moss SM, Gray A, Marteau T, et al. Evaluation of HPV/LBC Cervical Screening Pilot Studies: Report to the Department of Health (Revised October 2004). Sheffield, UK: National Health Service Cancer Screening Programmes; 2004.
  • 2
    Northern Ireland Cervical Screening Programme. Annual Report and Statistical Bulletin, 2009-2010. Belfast, Northern Ireland: Quality Assurance Reference Centre; 2010.
  • 3
    The National Health Service (NHS) Information Centre, Screening and Immunisation Team. NHS Cancer Screening Programmes (CSP) Statistical Bulletin, England 2010-2011. Sheffield, UK: NHSCSP; 2011.
  • 4
    Cervical Screening Wales. A Report on the Implementation of Liquid Based Cytology in Wales: July 2004 to December 2005. Cardiff, UK: Cervical Screening Wales; 2007.
  • 5
    Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:15791588.
  • 6
    Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised control trial. Lancet Oncol. 2010;11:249257.
  • 7
    Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13:51150, iii-iv.
  • 8
    National Health Service (NHS) Cancer Screening Programmes (CSP). Achievable Standards, Benchmarks for Reporting and Criteria for Evaluating Cervical Cytopathology. 3rd ed. NHSCSP Publ. No. 1. Sheffield, UK: NHSCSP; 2012.
  • 9
    Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:21142119.
  • 10
    McMenamin M, McKenna M. Effect of glacial acetic acid treatment of cervical ThinPrep specimens on HPV DNA detection with the cobas 4800 HPV test. Cytopathology. 2013;24:321326.
  • 11
    Feng J, Husain M. Reflex high-risk human papillomavirus DNA testing (Hybrid Capture 2) of bloody ThinPrep specimens with atypical squamous cells of undetermined significance interpretation; does pretreatment with acetic acid affect test performance? Cancer Cytopathol. 2005;105:452456.
  • 12
    Cytyc Corporation (Hologic). ThinPrep 3000 Processor Operator's Manual. Bedford, MA: Cytyc Corporation (Hologic); 2000.
  • 13
    Roche Molecular Systems. cobas HPV Test Sample Color Reference Guide. Pleasanton, CA: Roche Molecular Systems; 2012.
  • 14
    Agoff SN, Dean T, Nixon BK, et al. The efficacy of reprocessing unsatisfactory cervicovaginal ThinPrep specimens with and without glacial acetic acid: effect on Hybrid Capture II human papillomavirus testing and clinical follow-up. Am J Clin Pathol. 2002;118:727732.
  • 15
    Roche Molecular Systems. cobas 4800 HPV Test [package insert]. Doc Rev 2.0. Pleasanton, CA: Roche Molecular Systems; 2010.
  • 16
    Bowring J, Albrow R, Fisher A, et al. A prospective study of human papillomavirus (HPV) testing to resolve uncertainty in colposcopy. Cytopathology. 2013;24:309313.